```html

Jaundice of Hepatitis C: A Complete Medical Guide

Overview

Jaundice is a yellow discoloration of the skin, sclerae (the whites of the eyes), and mucous membranes caused by elevated levels of bilirubin in the blood. When jaundice occurs in a person infected with hepatitis C virus (HCV), it signals that the liver is struggling to process bilirubin because of inflammation, injury, or advanced scarring (cirrhosis).

Hepatitis C is a blood‑borne viral infection that primarily damages the liver. Worldwide, an estimated 58 million people are chronically infected with HCV, and about 1.5 million new infections occur each year (World Health Organization, 2023). In the United States, roughly 2.4 million individuals live with chronic hepatitis C, many of whom are unaware of their infection.<sup>1</sup> Only a minority of those with HCV develop clinically apparent jaundice—most cases arise when the disease progresses to moderate or severe liver inflammation or when an acute flare occurs.

Jaundice can appear at any age but is most common in adults between 30 and 60 years, reflecting the typical time lag between infection and liver damage. People with co‑existing liver disease (e.g., alcoholic liver disease, non‑alcoholic fatty liver disease), HIV infection, or who have received certain hepatotoxic medications are at higher risk of developing jaundice from hepatitis C.

Symptoms

Jaundice itself is a sign, not a disease, and is usually accompanied by a constellation of other hepatic and systemic symptoms. The following list includes the most frequently reported manifestations in patients with hepatitis C‑related jaundice:

• Yellowing of skin and eyes – The hallmark sign; usually begins on the face and spreads to the trunk and limbs.
• Dark urine – Concentrated urine due to excreted bilirubin.
• Pale, clay‑colored stools – Lack of bile pigments reaching the intestines.
• Pruritus (itching) – Bile salts deposited in the skin can cause uncomfortable itching.
• Fatigue and weakness – Common in chronic liver disease.
• Abdominal discomfort, especially in the right upper quadrant where the liver resides.
• Loss of appetite and nausea – May lead to unintentional weight loss.
• Fever – May indicate an acute flare or superimposed infection.
• Joint and muscle aches – Occasionally seen in chronic HCV (“mixed cryoglobulinemia”).
• Bruising or easy bleeding – Result of impaired production of clotting factors.
• Confusion, memory problems, or “brain fog” – Signs of hepatic encephalopathy in advanced disease.

Causes and Risk Factors

How jaundice develops in hepatitis C

Hepatitis C damages liver cells (hepatocytes) through direct viral cytopathic effects and immune‑mediated inflammation. When enough hepatocytes are injured, the liver’s ability to conjugate (make water‑soluble) bilirubin declines. Unconjugated bilirubin builds up in the bloodstream, leading to jaundice. In chronic infection, repeated cycles of inflammation can cause fibrosis and cirrhosis, further compromising bilirubin clearance.

Key risk factors

• Intravenous drug use – The most common transmission route in high‑income countries.
• Blood transfusions before 1992 – Screening for HCV became routine in many nations after this year.
• Unsafe medical practices – Reuse of needles, inadequate sterilization of equipment.
• Sexual contact with an infected partner – Higher risk for men who have sex with men (MSM) and individuals with HIV.
• Mother‑to‑child transmission – Occurs in ~5 % of births to infected mothers.
• Co‑infection with HIV or hepatitis B – Accelerates liver injury.
• Heavy alcohol use – Synergistic hepatotoxicity increases the chance of jaundice.
• Obesity & metabolic syndrome – Promote fatty liver disease, compounding HCV damage.

Diagnosis

Diagnosing jaundice in the context of hepatitis C involves confirming both the presence of elevated bilirubin and an active HCV infection, while also assessing the extent of liver injury.

Laboratory tests

• Total and direct bilirubin – Quantifies bilirubin levels; >2.5 mg/dL often correlates with visible jaundice.
• Liver function panel – Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma‑glutamyl transferase (GGT), and albumin. Marked elevation of ALT/AST (>10× upper limit) suggests active inflammation.
• Hepatitis C antibody (anti‑HCV) – Initial screening.
• HCV RNA polymerase chain reaction (PCR) – Confirms active viral replication and quantifies viral load.
• Complete blood count (CBC) – Looks for anemia, leukopenia, thrombocytopenia (often seen in cirrhosis).
• Coagulation profile (PT/INR) – Assesses synthetic function of the liver.

Imaging studies

• Abdominal ultrasound – First‑line to evaluate liver size, texture, presence of nodules, and biliary obstruction.
• Transient elastography (FibroScan) – Non‑invasive measurement of liver stiffness; helps stage fibrosis.
• CT or MRI – Reserved for complex cases or when a focal lesion is suspected.

Special procedures

• Liver biopsy – Considered when non‑invasive tests are inconclusive or when other liver diseases must be ruled out.

Treatment Options

Management focuses on eliminating the virus, reducing inflammation, and supporting liver function. Modern direct‑acting antiviral (DAA) regimens have transformed hepatitis C therapy, achieving cure rates >95 %.

Antiviral medications

Regimen (pan‑genotypic)	Duration	Cure rate (SVR12)
Sofosbuvir/velpatasvir (Epclusa)	12 weeks	97‑99 %
Glecaprevir/pibrentasvir (Mavyret)	8‑12 weeks	96‑98 %
Sofosbuvir/ledipasvir (Harvoni) – genotype 1	12 weeks	95‑99 %

These agents are taken orally once daily, have minimal side effects, and are safe for most patients, including those with compensated cirrhosis. For decompensated cirrhosis, ribavirin may be added, and treatment duration may be extended to 24 weeks.

Adjunctive therapies for jaundice

• Ursodeoxycholic acid (UDCA) – May improve bile flow in cholestatic presentations.
• Vitamin K – Corrects coagulopathy if INR is elevated.
• Phototherapy – Rarely needed in adults, but high‑intensity light can lower bilirubin in severe cases.

Lifestyle and supportive care

• Alcohol abstinence – Essential to prevent further liver injury.
• Balanced diet – Emphasize lean protein, whole grains, fruits, and vegetables; limit saturated fat and added sugars.
• Hydration – Supports renal clearance of bilirubin.
• Weight management – Reduces fatty infiltration of the liver.

Living with Jaundice of Hepatitis C

Daily management tips

• Medication adherence – Set daily alarms; use pill organizers.
• Monitor skin and eye color – Take a weekly photo to spot subtle changes.
• Track laboratory results – Keep a log of bilirubin, ALT/AST, and viral load trends.
• Protect skin from itching – Use gentle, fragrance‑free moisturizers; cool compresses can soothe.
• Stay up to date with vaccinations – Hepatitis A & B, influenza, and COVID‑19 are recommended.
• Regular follow‑up – Every 3–6 months with a hepatology‑trained provider even after cure, especially if cirrhosis was present.

Emotional and social well‑being

Living with a chronic liver disease can be stressful. Consider joining a support group (e.g., Hepatitis C Support Network) and seek counseling if anxiety or depression arises. The stigma associated with viral hepatitis often lessens after successful treatment, but emotional support remains important.

Prevention

Because jaundice is a downstream effect of HCV infection, preventing